Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 145-152 , 15 February 2003

The diagnosis of primary progressive multiple sclerosis

  • Jerry S Wolinsky

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1-713-500-7048; fax: +1-713-500-7041.
    • ,
  • the PROMiSe Study Group

      Affiliations

    • The participating centers and principal investigators of the PROMiSe trial are listed in the acknowledgement.

References 

  1. Charcot J-M. In: Histologie de la sclerose en plaques. vol. 41:Paris: Gazette Hopital; 1868;p. 554–558
  2. McAlpine D. Multiple sclerosis: a review. Br. Med. J. 1973;2:292–295
  3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907–911
  4. Jacobs LD, Beck RW, Simon JH, et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 2000;343:898–904
  5. Comi G, Filippi M, Barkhof F, et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576–1582
  6. Stevenson VL, Miller DH, Rovaris M, et al.  Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology. 1999;52:839–845
  7. Poser CM, Paty DW, Scheinberg L, et al.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227–231
  8. Kappos L  for the European Study Group on interferon beta-1b in secondary progressive MS . Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491–1497
  9. Francis G  Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group . Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56:1496–1504
  10. Lucchinetti C, Bruck W, Parisi J, et al.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2001;47:707–717
  11. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain. 1994;117:759–765
  12. Wolinsky JS, Narayana PA, He R. Overview of treatment trials: early baseline clinical and MRI data of the PROMiSe trial. In:  Filippi M,  Comi G editor. Primary progressive multiple sclerosis. Milano: Springer-Verlag Italia; 2002;p. 47–61
  13. Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann. N.Y. Acad. Med. 1965;122:552–568
  14. Thompson AJ, Polman CH, Miller DH, et al.  Primary progressive multiple sclerosis. Brain. 1997;120:1085–1096
  15. McDonnell GV, Hawkins SA. Application of the Poser criteria in primary progressive multiple sclerosis. Ann. Neurol. 1997;42:982–983
  16. Thompson AJ, Montalban X, Barkhof F, et al.  Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann. Neurol. 2000;47:831–835
  17. McDonald WI, Compston A, Edan G, et al.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001;50:121–127
  18. McDonnell GV, Hawkins SA. Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J. Neurol. Neurosurg. Psychiatry. 1998;64:451–454
  19. Cottrell DA, Kremenchutzky M, Rice GP, et al.  The natural history of multiple sclerosis: a geographically based study: 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122:625–639
  20. Bashir K, Whitaker JN. Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology. 1999;53:765–771
  21. Barkhof F, Filippi M, Miller DH, et al.  Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120:2059–2069
  22. Thorpe JW, Kidd D, Moseley IF, et al.  Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain. 1996;119:709–714
  23. Filippi M, Campi A, Martinelli V, et al.  Comparison of triple dose versus standard dose gadolinium–DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1995;59:540–544
  24. Filippi M, Rovaris M, Gasperini C, et al.  A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium–DTPA for monitoring disease activity in primary progressive multiple sclerosis. J. Neuroimaging. 1998;8:88–93
  25. Rovaris M, Comi G, Filippi M. Magnetization transfer and diffusion tensor magnetic resonance imaging. In:  Filippi M,  Comi G editor. Primary progressive multiple sclerosis. Milano: Springer-Verlag Italia; 2002;p. 77–88
  26. Caramanos Z, Santos AC, Francis SJ, Narayanan S, Pelletier D, Arnold DL. Proton magnetic resonance spectroscopy. In:  Filippi M,  Comi G editor. Primary progressive multiple sclerosis. Milano: Springer-Verlag Italia; 2002;p. 89–112
  27. Andersson M, Alvarez-Cermeno J, Bernardi G, et al.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry. 1994;57:897–902
  28. Andersson PB, Waubant E, Gee L, Goodkin DE. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch. Neurol. 1999;56:1138–1142
  29. Cottrell DA, Kremenchutzky M, Rice GP, Hader W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study: 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain. 1999;122:641–647
  30. Pirttila T, Nurmikko T. CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis. Acta Neurol. Scand. 1995;92:468–471
  31. Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;54:1720–1725
  32. Kurtzke JF. Clinical definition for multiple sclerosis treatment trials. Ann. Neurol. 1994;36:S73–S79

PII: S0022-510X(02)00346-5

Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 145-152 , 15 February 2003

Article Tools

* Image Usage & Resolution